Development of Probiotic Tablets Using Microparticles: Viability Studies and Stability Studies

Alternative vectors to deliver viable cells of probiotics, to those conferring limited resistance to gastrointestinal conditions, still need to be sought. Therefore the main goal of the study was to develop tablets able to protect entrapped probiotic bacteria from gastric acidity, thus providing an...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:AAPS PharmSciTech 2013-03, Vol.14 (1), p.121-127
Hauptverfasser: e Silva, J. P. Sousa, Sousa, Sérgio C., Costa, Paulo, Cerdeira, Emília, Amaral, Maria H., Lobo, José Sousa, Gomes, Ana M., Pintado, Maria M., Rodrigues, Dina, Rocha-Santos, Teresa, Freitas, Ana C.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 127
container_issue 1
container_start_page 121
container_title AAPS PharmSciTech
container_volume 14
creator e Silva, J. P. Sousa
Sousa, Sérgio C.
Costa, Paulo
Cerdeira, Emília
Amaral, Maria H.
Lobo, José Sousa
Gomes, Ana M.
Pintado, Maria M.
Rodrigues, Dina
Rocha-Santos, Teresa
Freitas, Ana C.
description Alternative vectors to deliver viable cells of probiotics, to those conferring limited resistance to gastrointestinal conditions, still need to be sought. Therefore the main goal of the study was to develop tablets able to protect entrapped probiotic bacteria from gastric acidity, thus providing an easily manufacturing scale-up dosage form to deliver probiotics to the vicinity of the human colon. Whey protein concentrate microparticles with Lactobacillus paracasei L26 were produced by spray-drying and incorporated in tablets with cellulose acetate phthalate and sodium croscarmellose. The viability of L . paracasei L.26 throughout tableting as well as its gastric resistance and release from the tablets were evaluated. Storage stability of L . paracasei L26 tablets was also performed by evaluation of viable cells throughout 60 days at 23°C and 33% relative humidity. A decrease of approximately one logarithmic cycle was observed after the acid stage and the release of L . paracasei L26 from the tablets occurred only after 4 h in the conditions tested. Microencapsulated L . paracasei L26 in tablets revealed some susceptibility to the storage conditions tested since the number of viable cells decreased 2 log cycles after 60 days of storage. However, the viability of L . paracasei L26 after 45 days of storage did not reveal significant susceptibility upon exposure to simulated gastrointestinal conditions. The developed probiotic tablets revealed to be potential vectors for delivering viable cells of L . paracasei L26 and probably other probiotics to persons/patients who might benefit from probiotic therapy.
doi_str_mv 10.1208/s12249-012-9898-9
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3581639</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1427005869</sourcerecordid><originalsourceid>FETCH-LOGICAL-c503t-d2cfa01ac3ec0427311db6f079e4d8aa922ba2e704264602fabc1e4961d52a6a3</originalsourceid><addsrcrecordid>eNqNkUtLxTAQhYMovn-AG-nSTTWZtL2NC0F8g6LgY2mYptNrpLe5Jq3gvzeXq6IuxFWGnDMfM3MY2xJ8VwAv94IAyFTKBaSqVGWqFtiqyCVPlZKw-K1eYWshPHMOUii5zFZAgpRQwip7PKZXat10Ql2fuCa58a6yrrcmucOqpT4k98F24-TKGu-m6KPSUthPHixWtrX9W3LbD7WlkGBXx_rX7wZbarANtPnxrrP705O7o_P08vrs4ujwMjU5l31ag2mQCzSSDM9gJIWoq6LhI0VZXSIqgAqBRlErsoJDg5URlKlC1DlggXKdHcy506GaUG3iNh5bPfV2gv5NO7T6p9LZJz12r1rmpSikioCdD4B3LwOFXk9sMNS22JEbghZxKs7zsviHVQoos5znMlrF3BqPF4Kn5msiwfUsQj2PUMcI9SxCPcNvf1_lq-Mzs2iAuSFEqRuT189u8F087x_Ud5vyqMo</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1312845053</pqid></control><display><type>article</type><title>Development of Probiotic Tablets Using Microparticles: Viability Studies and Stability Studies</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>e Silva, J. P. Sousa ; Sousa, Sérgio C. ; Costa, Paulo ; Cerdeira, Emília ; Amaral, Maria H. ; Lobo, José Sousa ; Gomes, Ana M. ; Pintado, Maria M. ; Rodrigues, Dina ; Rocha-Santos, Teresa ; Freitas, Ana C.</creator><creatorcontrib>e Silva, J. P. Sousa ; Sousa, Sérgio C. ; Costa, Paulo ; Cerdeira, Emília ; Amaral, Maria H. ; Lobo, José Sousa ; Gomes, Ana M. ; Pintado, Maria M. ; Rodrigues, Dina ; Rocha-Santos, Teresa ; Freitas, Ana C.</creatorcontrib><description>Alternative vectors to deliver viable cells of probiotics, to those conferring limited resistance to gastrointestinal conditions, still need to be sought. Therefore the main goal of the study was to develop tablets able to protect entrapped probiotic bacteria from gastric acidity, thus providing an easily manufacturing scale-up dosage form to deliver probiotics to the vicinity of the human colon. Whey protein concentrate microparticles with Lactobacillus paracasei L26 were produced by spray-drying and incorporated in tablets with cellulose acetate phthalate and sodium croscarmellose. The viability of L . paracasei L.26 throughout tableting as well as its gastric resistance and release from the tablets were evaluated. Storage stability of L . paracasei L26 tablets was also performed by evaluation of viable cells throughout 60 days at 23°C and 33% relative humidity. A decrease of approximately one logarithmic cycle was observed after the acid stage and the release of L . paracasei L26 from the tablets occurred only after 4 h in the conditions tested. Microencapsulated L . paracasei L26 in tablets revealed some susceptibility to the storage conditions tested since the number of viable cells decreased 2 log cycles after 60 days of storage. However, the viability of L . paracasei L26 after 45 days of storage did not reveal significant susceptibility upon exposure to simulated gastrointestinal conditions. The developed probiotic tablets revealed to be potential vectors for delivering viable cells of L . paracasei L26 and probably other probiotics to persons/patients who might benefit from probiotic therapy.</description><identifier>ISSN: 1530-9932</identifier><identifier>EISSN: 1530-9932</identifier><identifier>DOI: 10.1208/s12249-012-9898-9</identifier><identifier>PMID: 23233282</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject>Biochemistry ; Biomedical and Life Sciences ; Biomedicine ; Biotechnology ; Lactobacillus ; Lactobacillus paracasei ; Pharmacology/Toxicology ; Pharmacy ; Probiotics ; Research Article ; Tablets</subject><ispartof>AAPS PharmSciTech, 2013-03, Vol.14 (1), p.121-127</ispartof><rights>American Association of Pharmaceutical Scientists 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c503t-d2cfa01ac3ec0427311db6f079e4d8aa922ba2e704264602fabc1e4961d52a6a3</citedby><cites>FETCH-LOGICAL-c503t-d2cfa01ac3ec0427311db6f079e4d8aa922ba2e704264602fabc1e4961d52a6a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3581639/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3581639/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,41464,42533,51294,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23233282$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>e Silva, J. P. Sousa</creatorcontrib><creatorcontrib>Sousa, Sérgio C.</creatorcontrib><creatorcontrib>Costa, Paulo</creatorcontrib><creatorcontrib>Cerdeira, Emília</creatorcontrib><creatorcontrib>Amaral, Maria H.</creatorcontrib><creatorcontrib>Lobo, José Sousa</creatorcontrib><creatorcontrib>Gomes, Ana M.</creatorcontrib><creatorcontrib>Pintado, Maria M.</creatorcontrib><creatorcontrib>Rodrigues, Dina</creatorcontrib><creatorcontrib>Rocha-Santos, Teresa</creatorcontrib><creatorcontrib>Freitas, Ana C.</creatorcontrib><title>Development of Probiotic Tablets Using Microparticles: Viability Studies and Stability Studies</title><title>AAPS PharmSciTech</title><addtitle>AAPS PharmSciTech</addtitle><addtitle>AAPS PharmSciTech</addtitle><description>Alternative vectors to deliver viable cells of probiotics, to those conferring limited resistance to gastrointestinal conditions, still need to be sought. Therefore the main goal of the study was to develop tablets able to protect entrapped probiotic bacteria from gastric acidity, thus providing an easily manufacturing scale-up dosage form to deliver probiotics to the vicinity of the human colon. Whey protein concentrate microparticles with Lactobacillus paracasei L26 were produced by spray-drying and incorporated in tablets with cellulose acetate phthalate and sodium croscarmellose. The viability of L . paracasei L.26 throughout tableting as well as its gastric resistance and release from the tablets were evaluated. Storage stability of L . paracasei L26 tablets was also performed by evaluation of viable cells throughout 60 days at 23°C and 33% relative humidity. A decrease of approximately one logarithmic cycle was observed after the acid stage and the release of L . paracasei L26 from the tablets occurred only after 4 h in the conditions tested. Microencapsulated L . paracasei L26 in tablets revealed some susceptibility to the storage conditions tested since the number of viable cells decreased 2 log cycles after 60 days of storage. However, the viability of L . paracasei L26 after 45 days of storage did not reveal significant susceptibility upon exposure to simulated gastrointestinal conditions. The developed probiotic tablets revealed to be potential vectors for delivering viable cells of L . paracasei L26 and probably other probiotics to persons/patients who might benefit from probiotic therapy.</description><subject>Biochemistry</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Biotechnology</subject><subject>Lactobacillus</subject><subject>Lactobacillus paracasei</subject><subject>Pharmacology/Toxicology</subject><subject>Pharmacy</subject><subject>Probiotics</subject><subject>Research Article</subject><subject>Tablets</subject><issn>1530-9932</issn><issn>1530-9932</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkUtLxTAQhYMovn-AG-nSTTWZtL2NC0F8g6LgY2mYptNrpLe5Jq3gvzeXq6IuxFWGnDMfM3MY2xJ8VwAv94IAyFTKBaSqVGWqFtiqyCVPlZKw-K1eYWshPHMOUii5zFZAgpRQwip7PKZXat10Ql2fuCa58a6yrrcmucOqpT4k98F24-TKGu-m6KPSUthPHixWtrX9W3LbD7WlkGBXx_rX7wZbarANtPnxrrP705O7o_P08vrs4ujwMjU5l31ag2mQCzSSDM9gJIWoq6LhI0VZXSIqgAqBRlErsoJDg5URlKlC1DlggXKdHcy506GaUG3iNh5bPfV2gv5NO7T6p9LZJz12r1rmpSikioCdD4B3LwOFXk9sMNS22JEbghZxKs7zsviHVQoos5znMlrF3BqPF4Kn5msiwfUsQj2PUMcI9SxCPcNvf1_lq-Mzs2iAuSFEqRuT189u8F087x_Ud5vyqMo</recordid><startdate>20130301</startdate><enddate>20130301</enddate><creator>e Silva, J. P. Sousa</creator><creator>Sousa, Sérgio C.</creator><creator>Costa, Paulo</creator><creator>Cerdeira, Emília</creator><creator>Amaral, Maria H.</creator><creator>Lobo, José Sousa</creator><creator>Gomes, Ana M.</creator><creator>Pintado, Maria M.</creator><creator>Rodrigues, Dina</creator><creator>Rocha-Santos, Teresa</creator><creator>Freitas, Ana C.</creator><general>Springer US</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7QL</scope><scope>7QO</scope><scope>7T7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>P64</scope><scope>5PM</scope></search><sort><creationdate>20130301</creationdate><title>Development of Probiotic Tablets Using Microparticles: Viability Studies and Stability Studies</title><author>e Silva, J. P. Sousa ; Sousa, Sérgio C. ; Costa, Paulo ; Cerdeira, Emília ; Amaral, Maria H. ; Lobo, José Sousa ; Gomes, Ana M. ; Pintado, Maria M. ; Rodrigues, Dina ; Rocha-Santos, Teresa ; Freitas, Ana C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c503t-d2cfa01ac3ec0427311db6f079e4d8aa922ba2e704264602fabc1e4961d52a6a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Biochemistry</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Biotechnology</topic><topic>Lactobacillus</topic><topic>Lactobacillus paracasei</topic><topic>Pharmacology/Toxicology</topic><topic>Pharmacy</topic><topic>Probiotics</topic><topic>Research Article</topic><topic>Tablets</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>e Silva, J. P. Sousa</creatorcontrib><creatorcontrib>Sousa, Sérgio C.</creatorcontrib><creatorcontrib>Costa, Paulo</creatorcontrib><creatorcontrib>Cerdeira, Emília</creatorcontrib><creatorcontrib>Amaral, Maria H.</creatorcontrib><creatorcontrib>Lobo, José Sousa</creatorcontrib><creatorcontrib>Gomes, Ana M.</creatorcontrib><creatorcontrib>Pintado, Maria M.</creatorcontrib><creatorcontrib>Rodrigues, Dina</creatorcontrib><creatorcontrib>Rocha-Santos, Teresa</creatorcontrib><creatorcontrib>Freitas, Ana C.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>AAPS PharmSciTech</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>e Silva, J. P. Sousa</au><au>Sousa, Sérgio C.</au><au>Costa, Paulo</au><au>Cerdeira, Emília</au><au>Amaral, Maria H.</au><au>Lobo, José Sousa</au><au>Gomes, Ana M.</au><au>Pintado, Maria M.</au><au>Rodrigues, Dina</au><au>Rocha-Santos, Teresa</au><au>Freitas, Ana C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development of Probiotic Tablets Using Microparticles: Viability Studies and Stability Studies</atitle><jtitle>AAPS PharmSciTech</jtitle><stitle>AAPS PharmSciTech</stitle><addtitle>AAPS PharmSciTech</addtitle><date>2013-03-01</date><risdate>2013</risdate><volume>14</volume><issue>1</issue><spage>121</spage><epage>127</epage><pages>121-127</pages><issn>1530-9932</issn><eissn>1530-9932</eissn><abstract>Alternative vectors to deliver viable cells of probiotics, to those conferring limited resistance to gastrointestinal conditions, still need to be sought. Therefore the main goal of the study was to develop tablets able to protect entrapped probiotic bacteria from gastric acidity, thus providing an easily manufacturing scale-up dosage form to deliver probiotics to the vicinity of the human colon. Whey protein concentrate microparticles with Lactobacillus paracasei L26 were produced by spray-drying and incorporated in tablets with cellulose acetate phthalate and sodium croscarmellose. The viability of L . paracasei L.26 throughout tableting as well as its gastric resistance and release from the tablets were evaluated. Storage stability of L . paracasei L26 tablets was also performed by evaluation of viable cells throughout 60 days at 23°C and 33% relative humidity. A decrease of approximately one logarithmic cycle was observed after the acid stage and the release of L . paracasei L26 from the tablets occurred only after 4 h in the conditions tested. Microencapsulated L . paracasei L26 in tablets revealed some susceptibility to the storage conditions tested since the number of viable cells decreased 2 log cycles after 60 days of storage. However, the viability of L . paracasei L26 after 45 days of storage did not reveal significant susceptibility upon exposure to simulated gastrointestinal conditions. The developed probiotic tablets revealed to be potential vectors for delivering viable cells of L . paracasei L26 and probably other probiotics to persons/patients who might benefit from probiotic therapy.</abstract><cop>Boston</cop><pub>Springer US</pub><pmid>23233282</pmid><doi>10.1208/s12249-012-9898-9</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1530-9932
ispartof AAPS PharmSciTech, 2013-03, Vol.14 (1), p.121-127
issn 1530-9932
1530-9932
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3581639
source MEDLINE; Springer Nature - Complete Springer Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Free Full-Text Journals in Chemistry
subjects Biochemistry
Biomedical and Life Sciences
Biomedicine
Biotechnology
Lactobacillus
Lactobacillus paracasei
Pharmacology/Toxicology
Pharmacy
Probiotics
Research Article
Tablets
title Development of Probiotic Tablets Using Microparticles: Viability Studies and Stability Studies
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T00%3A55%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20of%20Probiotic%20Tablets%20Using%20Microparticles:%20Viability%20Studies%20and%20Stability%20Studies&rft.jtitle=AAPS%20PharmSciTech&rft.au=e%20Silva,%20J.%20P.%20Sousa&rft.date=2013-03-01&rft.volume=14&rft.issue=1&rft.spage=121&rft.epage=127&rft.pages=121-127&rft.issn=1530-9932&rft.eissn=1530-9932&rft_id=info:doi/10.1208/s12249-012-9898-9&rft_dat=%3Cproquest_pubme%3E1427005869%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1312845053&rft_id=info:pmid/23233282&rfr_iscdi=true